Back رانيبيزوماب Arabic Ranibizumab German Ranibizumab Spanish רניביזומאב HE Ranibizumab Italian ラニビズマブ Japanese ରାନିବିଜୁମାବ OR Ranibizumab Polish Ranibizumabe Portuguese Ранибизумаб Russian
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Vascular endothelial growth factor A (VEGF-A) |
| Clinical data | |
| Trade names | Lucentis, others |
| Biosimilars | Byooviz,[1][2] Cimerli,[3] Ranivisio,[4] Raniviz,[5] Susvimo,[6] Ximluci[7] ranibizumab-eqrn,[3] ranibizumab-nuna[1] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607044 |
| License data |
|
| Pregnancy category | |
| Routes of administration | Intravitreal injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | Approx. 9 days[12] |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2158H3282N562O681S12 |
| Molar mass | 48379.97 g·mol−1 |
  (what is this?) (verify) | |
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic[14] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis,[15] under the brand name Lucentis.[12][15][16] Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006,[16][12] and in the European Union in January 2007.
- ^ a b c "Byooviz Nuna- ranibizumab injection, solution". DailyMed. 27 April 2022. Archived from the original on 3 August 2022. Retrieved 2 August 2022.
- ^ a b "Byooviz EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c "Cimerli- ranibizumab-eqrn injection, solution". DailyMed. 19 October 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
- ^ a b Cite error: The named reference
Ranivisio EPARwas invoked but never defined (see the help page). - ^ a b "Raniviz APMDS". Therapeutic Goods Administration (TGA). 8 January 2024. Archived from the original on 8 February 2024. Retrieved 7 March 2024.
- ^ a b "Susvimo- ranibizumab injection, solution". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
- ^ a b Cite error: The named reference
Ximluci EPARwas invoked but never defined (see the help page). - ^ a b "AusPAR: Ranibizumab". Therapeutic Goods Administration (TGA). 9 December 2014. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
- ^ a b "Byooviz APMDS". Therapeutic Goods Administration (TGA). 6 September 2022. Retrieved 7 March 2024.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Summary Basis of Decision - Byooviz". Health Canada. 12 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
- ^ a b c d "Lucentis- ranibizumab injection, solution". DailyMed. Archived from the original on 21 September 2021. Retrieved 20 September 2021.
- ^ "Lucentis EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19–e22. doi:10.3928/01913913-20110308-02. PMID 21417187. Archived from the original on 1 October 2021. Retrieved 1 October 2021.
- ^ a b "Lucentis Fact Sheet". Genentech. Archived from the original on 28 October 2012. Retrieved 28 October 2012.
- ^ a b "Drug Approval Package: Lucentis (Ranibizumab) NDA #125156". U.S. Food and Drug Administration (FDA). 26 September 2006. Archived from the original on 2 August 2022. Retrieved 2 August 2022.